Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30110668 | 1.00 | CYP3A4 (0.59) | CYP3A4TNKSCTSS | |
| SCHEMBL17613271 | 0.90 | CYP3A4 (0.59) | CYP3A4CTSS | |
| SCHEMBL29658105 | 0.90 | CYP3A4 (0.59) | CYP3A4CTSS | |
| SCHEMBL31069427 | 0.89 | CYP3A4 (0.57) | CYP3A4 | |
| SCHEMBL15306210 | 0.87 | CYP3A4 (0.60) | CYP3A4TNKS | |
| SCHEMBL9940383 | 0.86 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL9979857 | 0.86 | CYP3A4 (0.62) | CYP3A4TNKS | |
| SCHEMBL17613266 | 0.85 | CYP3A4 (0.61) | CYP3A4TNKS | |
| SCHEMBL15301176 | 0.84 | CYP3A4 (0.56) | CYP3A4TNKS | |
| SCHEMBL16696084 | 0.83 | CYP3A4 (0.53) | CYP3A4CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085675-A1 | CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING RSV INFECTION | NIEDRAUER MARY LYNN (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4126023-A1 | STABILIZED VACCINE COMPOSITIONS | Janssen Vaccines & Prevention B.V. (NL) | 2023-02-08 | — | — | EP | disclosed |
| CN-115461076-A | Stabilized vaccine compositions | 扬森疫苗与预防公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021198413-A1 | STABILIZED VACCINE COMPOSITIONS | JANSSEN VACCINES & PREVENTION B.V. (NL) | 2021-10-07 | — | — | WO | disclosed |
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| EP-2651903-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | Janssen R&D Ireland (IE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080446-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | SBDS, CHUK, HAT1 | CYP3A4 34/4885TNKS 2070/4885CTSS 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.